VEGFA and hypertensive disorder: The observed adverse events were mostly anti-VEGF toxicities including hypertension, thrombosis, bleeding, proteinuria and dyslipidaemia, along with others such as febrile neutropenia, diarrhoea, myelosuppression, transaminitis, hypersensitivity and fatigue.